Summary
9.14 -0.14(-1.51%)07/05/2024
Precision Biosciences Inc (DTIL)
Precision Biosciences Inc (DTIL)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -1.93 | -5.53 | -30.12 | -36.28 | 2,355.67 | 1,656.68 | -35.41 | -47.59 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 9.14 | |
| Open | 9.26 | |
| High | 9.37 | |
| Low | 9.10 | |
| Volume | 21,489 | |
| Change | -0.18 | |
| Change % | -1.93 | |
| Avg Volume (20 Days) | 42,836 | |
| Volume/Avg Volume (20 Days) Ratio | 0.50 | |
| 52 Week Range | 0.28 - 19.43 | |
| Price vs 52 Week High | -52.96% | |
| Price vs 52 Week Low | 3,164.29% | |
| Range | -1.30 | |
| Gap Up/Down | -0.34 | |
Fundamentals | ||
| Market Capitalization (Mln) | 64 | |
| EBIDTA | -66,426,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 17.67 | |
| Book Value | 1.6880 | |
| Earnings Per Share | -0.5610 | |
| EPS Estimate Current Quarter | -0.5900 | |
| EPS Estimate Next Quarter | -0.6100 | |
| EPS Estimate Current Year | -0.6300 | |
| EPS Estimate Next Year | -2.0500 | |
| Diluted EPS (TTM) | -0.5610 | |
| Revenues | ||
| Profit Marging | -0.2691 | |
| Operating Marging (TTM) | -0.2722 | |
| Return on asset (TTM) | -0.1015 | |
| Return on equity (TTM) | -0.3844 | |
| Revenue TTM | 118,036,000 | |
| Revenue per share TTM | 2.0840 | |
| Quarterly Revenue Growth (YOY) | 2.2640 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 24,285,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 5.1397 | |
| Revenue Enterprise Value | 3.1554 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 60,767,300 | |
| Shares Float | 50,658,665 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 10.62 | |
| Institutions (%) | 49.39 | |
06/27 07:01 EST - businesswire.com
Precision BioSciences Announces Presentation at UMDF Mitochondrial Medicine 2024 Supporting Advancement of PBGENE-PMM Program Towards IND and/or CTA in 2025
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, is presenting data today at the United Mitochondrial Disease Foundation's (UMDF) Mitochondrial Medicine 2024 Conference being held in Cleveland, Ohio from June 26-29, 2024. “Our team is proud to share details from our.
Precision BioSciences Announces Presentation at UMDF Mitochondrial Medicine 2024 Supporting Advancement of PBGENE-PMM Program Towards IND and/or CTA in 2025
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, is presenting data today at the United Mitochondrial Disease Foundation's (UMDF) Mitochondrial Medicine 2024 Conference being held in Cleveland, Ohio from June 26-29, 2024. “Our team is proud to share details from our.
06/20 07:00 EST - businesswire.com
Precision BioSciences Expands Hepatitis Scientific Advisory Board with Addition of World-Class Clinical Investigators Mark Sulkowski, M.D. and Jordan Feld, M.D.
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced the appointment of Mark Sulkowski, M.D. and Jordan Feld, M.D., M.P.H. to its Hepatitis Scientific Advisory Board (SAB). Dr. Sulkowski and Dr. Feld will join Raymond Schinazi, Ph.D., DSc, inaugural membe.
Precision BioSciences Expands Hepatitis Scientific Advisory Board with Addition of World-Class Clinical Investigators Mark Sulkowski, M.D. and Jordan Feld, M.D.
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced the appointment of Mark Sulkowski, M.D. and Jordan Feld, M.D., M.P.H. to its Hepatitis Scientific Advisory Board (SAB). Dr. Sulkowski and Dr. Feld will join Raymond Schinazi, Ph.D., DSc, inaugural membe.
06/05 07:01 EST - businesswire.com
Precision BioSciences Presents New Preclinical Safety Data for PBGENE-HBV Clinical Candidate at the European Association for the Study of the Liver Congress
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, today announced that the company will present preclinical data for its PBGENE-HBV clinical candidate at the European Association for the Study of the Liver Congress (EASL), highlighting the differentiated ability of ARCUS to make efficient, durable, and targeted elimination edits. The poster present.
Precision BioSciences Presents New Preclinical Safety Data for PBGENE-HBV Clinical Candidate at the European Association for the Study of the Liver Congress
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, today announced that the company will present preclinical data for its PBGENE-HBV clinical candidate at the European Association for the Study of the Liver Congress (EASL), highlighting the differentiated ability of ARCUS to make efficient, durable, and targeted elimination edits. The poster present.
05/30 07:00 EST - businesswire.com
Precision BioSciences to Participate in Upcoming June Investor Conferences
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced that members of management will participate in the following upcoming investor conferences in June: Jefferies Global Healthcare Conference Date: Wednesday, June 5, 2024 Time: 1:30 pm – 1:55 pm ET Format.
Precision BioSciences to Participate in Upcoming June Investor Conferences
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced that members of management will participate in the following upcoming investor conferences in June: Jefferies Global Healthcare Conference Date: Wednesday, June 5, 2024 Time: 1:30 pm – 1:55 pm ET Format.
05/29 10:56 EST - zacks.com
Does Precision BioSciences (DTIL) Have the Potential to Rally 200.55% as Wall Street Analysts Expect?
The mean of analysts' price targets for Precision BioSciences (DTIL) points to a 200.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Does Precision BioSciences (DTIL) Have the Potential to Rally 200.55% as Wall Street Analysts Expect?
The mean of analysts' price targets for Precision BioSciences (DTIL) points to a 200.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
05/20 01:38 EST - https://www.defenseworld.net
Q2 2024 Earnings Estimate for Precision BioSciences, Inc. (NASDAQ:DTIL) Issued By HC Wainwright
Precision BioSciences, Inc. (NASDAQ:DTIL – Free Report) – Research analysts at HC Wainwright raised their Q2 2024 earnings estimates for shares of Precision BioSciences in a note issued to investors on Wednesday, May 15th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of ($0.77) for the quarter, up from their prior estimate of ($1.26). HC Wainwright currently has a “Buy” rating and a $60.00 price target on the stock. HC Wainwright also issued estimates for Precision BioSciences’ Q3 2024 earnings at ($0.79) EPS, Q4 2024 earnings at ($0.43) EPS, Q1 2025 earnings at ($0.39) EPS, Q2 2025 earnings at ($0.07) EPS, Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.26) EPS and FY2025 earnings at ($1.06) EPS. Precision BioSciences (NASDAQ:DTIL – Get Free Report) last announced its quarterly earnings data on Wednesday, March 27th. The company reported ($3.35) earnings per share (EPS) for the quarter, missing the consensus estimate of $3.00 by ($6.35). The firm had revenue of $7.04 million during the quarter, compared to the consensus estimate of $28.50 million. Precision BioSciences had a negative return on equity of 131.69% and a negative net margin of 48.10%. Separately, Guggenheim assumed coverage on shares of Precision BioSciences in a research note on Tuesday, April 30th. They set a “buy” rating and a $19.00 price target for the company. Read Our Latest Report on DTIL Precision BioSciences Price Performance Shares of NASDAQ DTIL opened at $12.40 on Monday. The company has a market cap of $85.93 million, a P/E ratio of -1.66 and a beta of 1.62. Precision BioSciences has a 1 year low of $8.25 and a 1 year high of $27.02. The firm has a 50-day simple moving average of $11.96 and a two-hundred day simple moving average of $11.98. Institutional Trading of Precision BioSciences A number of institutional investors and hedge funds have recently modified their holdings of DTIL. Curi Wealth Management LLC increased its stake in shares of Precision BioSciences by 42.0% during the third quarter. Curi Wealth Management LLC now owns 339,801 shares of the company’s stock worth $116,000 after purchasing an additional 100,530 shares in the last quarter. Tejara Capital Ltd increased its stake in shares of Precision BioSciences by 100.7% during the third quarter. Tejara Capital Ltd now owns 398,614 shares of the company’s stock worth $136,000 after purchasing an additional 200,000 shares in the last quarter. Acadian Asset Management LLC increased its stake in shares of Precision BioSciences by 8.3% during the third quarter. Acadian Asset Management LLC now owns 3,148,243 shares of the company’s stock worth $1,073,000 after purchasing an additional 242,425 shares in the last quarter. Finally, Janus Henderson Group PLC purchased a new stake in shares of Precision BioSciences during the first quarter worth about $7,739,000. Hedge funds and other institutional investors own 37.99% of the company’s stock. Precision BioSciences Company Profile (Get Free Report) Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. See Also Five stocks we like better than Precision BioSciences Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time MarketBeat Week in Review – 5/13 – 5/17 Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed Take-Two Interactive Software Offers 2nd Chance for Investors The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook
Q2 2024 Earnings Estimate for Precision BioSciences, Inc. (NASDAQ:DTIL) Issued By HC Wainwright
Precision BioSciences, Inc. (NASDAQ:DTIL – Free Report) – Research analysts at HC Wainwright raised their Q2 2024 earnings estimates for shares of Precision BioSciences in a note issued to investors on Wednesday, May 15th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of ($0.77) for the quarter, up from their prior estimate of ($1.26). HC Wainwright currently has a “Buy” rating and a $60.00 price target on the stock. HC Wainwright also issued estimates for Precision BioSciences’ Q3 2024 earnings at ($0.79) EPS, Q4 2024 earnings at ($0.43) EPS, Q1 2025 earnings at ($0.39) EPS, Q2 2025 earnings at ($0.07) EPS, Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.26) EPS and FY2025 earnings at ($1.06) EPS. Precision BioSciences (NASDAQ:DTIL – Get Free Report) last announced its quarterly earnings data on Wednesday, March 27th. The company reported ($3.35) earnings per share (EPS) for the quarter, missing the consensus estimate of $3.00 by ($6.35). The firm had revenue of $7.04 million during the quarter, compared to the consensus estimate of $28.50 million. Precision BioSciences had a negative return on equity of 131.69% and a negative net margin of 48.10%. Separately, Guggenheim assumed coverage on shares of Precision BioSciences in a research note on Tuesday, April 30th. They set a “buy” rating and a $19.00 price target for the company. Read Our Latest Report on DTIL Precision BioSciences Price Performance Shares of NASDAQ DTIL opened at $12.40 on Monday. The company has a market cap of $85.93 million, a P/E ratio of -1.66 and a beta of 1.62. Precision BioSciences has a 1 year low of $8.25 and a 1 year high of $27.02. The firm has a 50-day simple moving average of $11.96 and a two-hundred day simple moving average of $11.98. Institutional Trading of Precision BioSciences A number of institutional investors and hedge funds have recently modified their holdings of DTIL. Curi Wealth Management LLC increased its stake in shares of Precision BioSciences by 42.0% during the third quarter. Curi Wealth Management LLC now owns 339,801 shares of the company’s stock worth $116,000 after purchasing an additional 100,530 shares in the last quarter. Tejara Capital Ltd increased its stake in shares of Precision BioSciences by 100.7% during the third quarter. Tejara Capital Ltd now owns 398,614 shares of the company’s stock worth $136,000 after purchasing an additional 200,000 shares in the last quarter. Acadian Asset Management LLC increased its stake in shares of Precision BioSciences by 8.3% during the third quarter. Acadian Asset Management LLC now owns 3,148,243 shares of the company’s stock worth $1,073,000 after purchasing an additional 242,425 shares in the last quarter. Finally, Janus Henderson Group PLC purchased a new stake in shares of Precision BioSciences during the first quarter worth about $7,739,000. Hedge funds and other institutional investors own 37.99% of the company’s stock. Precision BioSciences Company Profile (Get Free Report) Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. See Also Five stocks we like better than Precision BioSciences Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time MarketBeat Week in Review – 5/13 – 5/17 Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed Take-Two Interactive Software Offers 2nd Chance for Investors The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook
05/17 07:00 EST - businesswire.com
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that, on May 13, 2024, the Compensation Committee of Precision's Board of Directors approved the grant of inducement awards to new employees under the Precision BioSciences, Inc. 2021 Employment Inducem.
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that, on May 13, 2024, the Compensation Committee of Precision's Board of Directors approved the grant of inducement awards to new employees under the Precision BioSciences, Inc. 2021 Employment Inducem.
05/13 07:00 EST - businesswire.com
Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, announced financial results for the first quarter ended March 31, 2024, and provided a business update. “In 2024, Precision is focused on strong execution as we advance our wholly owned Hepatitis B virus (HBV) and prim.
Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, announced financial results for the first quarter ended March 31, 2024, and provided a business update. “In 2024, Precision is focused on strong execution as we advance our wholly owned Hepatitis B virus (HBV) and prim.
05/08 08:15 EST - businesswire.com
Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL) (the “Company”), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, elimination, and excision, today announced that it has entered into a definitive subscription agreement, pursuant to which the Company will issue and sell in a non-brokered private placement to members of its senior leadership te.
Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL) (the “Company”), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, elimination, and excision, today announced that it has entered into a definitive subscription agreement, pursuant to which the Company will issue and sell in a non-brokered private placement to members of its senior leadership te.
05/07 16:30 EST - businesswire.com
Precision BioSciences to Report First Quarter Results on May 13, 2024
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced that it will publish financial results for the first quarter 2024 and provide a business update on Monday, May 13, 2024. About Precision BioSciences, Inc. Precision BioSciences, Inc. is an advanced gene.
Precision BioSciences to Report First Quarter Results on May 13, 2024
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced that it will publish financial results for the first quarter 2024 and provide a business update on Monday, May 13, 2024. About Precision BioSciences, Inc. Precision BioSciences, Inc. is an advanced gene.
05/07 08:30 EST - businesswire.com
Precision BioSciences Announces Receipt of FDA Fast Track Designation for ECUR-506, iECURE's Program for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, elimination, and excision, today announced that its partner iECURE has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for ECUR-506. ECUR-506 is iECURE's in vivo gene insertion program designed to treat neonatal.
Precision BioSciences Announces Receipt of FDA Fast Track Designation for ECUR-506, iECURE's Program for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, elimination, and excision, today announced that its partner iECURE has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for ECUR-506. ECUR-506 is iECURE's in vivo gene insertion program designed to treat neonatal.
05/07 08:00 EST - businesswire.com
iECURE Receives FDA Fast Track Designation for ECUR-506 for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency
PHILADELPHIA--(BUSINESS WIRE)--iECURE, Inc., a gene editing company focused on the development of mutation-agnostic in vivo gene insertion, or knock-in, editing therapies for the treatment of liver disorders with significant unmet need, announced today that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for ECUR-506, the company's in vivo gene insertion program designed to treat neonatal onset Ornithine Transcarbamylase (OTC) deficiency. The Fast Track d.
iECURE Receives FDA Fast Track Designation for ECUR-506 for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency
PHILADELPHIA--(BUSINESS WIRE)--iECURE, Inc., a gene editing company focused on the development of mutation-agnostic in vivo gene insertion, or knock-in, editing therapies for the treatment of liver disorders with significant unmet need, announced today that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for ECUR-506, the company's in vivo gene insertion program designed to treat neonatal onset Ornithine Transcarbamylase (OTC) deficiency. The Fast Track d.
05/01 07:05 EST - businesswire.com
Precision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced that the company will present late-breaking preclinical data from its clinical candidate, PBGENE-HBV, for the treatment of chronic hepatitis B (HBV) during a poster presentation at the European Associat.
Precision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced that the company will present late-breaking preclinical data from its clinical candidate, PBGENE-HBV, for the treatment of chronic hepatitis B (HBV) during a poster presentation at the European Associat.
04/16 16:15 EST - businesswire.com
Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company, today announced the anticipated return of three programs from Prevail Therapeutics Inc., a wholly owned subsidiary of Eli Lilly and Company. Precision exercised its option to regain rights for the programs following Prevail Therapeutics' decision to conclude the collaboration. Precision uses its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated.
Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company, today announced the anticipated return of three programs from Prevail Therapeutics Inc., a wholly owned subsidiary of Eli Lilly and Company. Precision exercised its option to regain rights for the programs following Prevail Therapeutics' decision to conclude the collaboration. Precision uses its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated.
04/11 10:55 EST - zacks.com
Precision BioSciences (DTIL) Now Trades Above Golden Cross: Time to Buy?
After reaching an important support level, Precision BioSciences, Inc. (DTIL) could be a good stock pick from a technical perspective. DTIL recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
Precision BioSciences (DTIL) Now Trades Above Golden Cross: Time to Buy?
After reaching an important support level, Precision BioSciences, Inc. (DTIL) could be a good stock pick from a technical perspective. DTIL recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
04/04 11:00 EST - businesswire.com
iECURE Announces FDA Clearance of Investigational New Drug Application for ECUR-506 to Initiate OTC-HOPE Trial for Treatment of Neonatal Onset Ornithine Transcarbamylase Deficiency in the U.S.
PHILADELPHIA--(BUSINESS WIRE)--iECURE, Inc., a gene editing company focused on the development of mutation-agnostic in vivo gene insertion, or knock-in, editing therapies for the treatment of liver disorders with significant unmet need, announced today clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) for ECUR-506 in Ornithine Transcarbamylase (OTC) deficiency. ECUR-506 will be evaluated in the OTC-HOPE study in newborn males with genet.
iECURE Announces FDA Clearance of Investigational New Drug Application for ECUR-506 to Initiate OTC-HOPE Trial for Treatment of Neonatal Onset Ornithine Transcarbamylase Deficiency in the U.S.
PHILADELPHIA--(BUSINESS WIRE)--iECURE, Inc., a gene editing company focused on the development of mutation-agnostic in vivo gene insertion, or knock-in, editing therapies for the treatment of liver disorders with significant unmet need, announced today clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) for ECUR-506 in Ornithine Transcarbamylase (OTC) deficiency. ECUR-506 will be evaluated in the OTC-HOPE study in newborn males with genet.
04/02 10:56 EST - zacks.com
Wall Street Analysts Predict a 407.94% Upside in Precision BioSciences (DTIL): Here's What You Should Know
The consensus price target hints at a 407.9% upside potential for Precision BioSciences (DTIL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Predict a 407.94% Upside in Precision BioSciences (DTIL): Here's What You Should Know
The consensus price target hints at a 407.9% upside potential for Precision BioSciences (DTIL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
04/02 07:51 EST - zacks.com
Precision BioSciences (DTIL) Soars 13.4%: Is Further Upside Left in the Stock?
Precision BioSciences (DTIL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Precision BioSciences (DTIL) Soars 13.4%: Is Further Upside Left in the Stock?
Precision BioSciences (DTIL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
03/27 09:10 EST - zacks.com
Precision BioSciences (DTIL) Reports Q4 Loss, Lags Revenue Estimates
Precision BioSciences (DTIL) came out with a quarterly loss of $3.35 per share versus the Zacks Consensus Estimate of $3. This compares to loss of $7.81 per share a year ago.
Precision BioSciences (DTIL) Reports Q4 Loss, Lags Revenue Estimates
Precision BioSciences (DTIL) came out with a quarterly loss of $3.35 per share versus the Zacks Consensus Estimate of $3. This compares to loss of $7.81 per share a year ago.
03/27 06:45 EST - businesswire.com
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced financial results for the fourth quarter and fiscal year ended December 31, 2023 and provided a business update. “2023 was a transformative year for Precision BioSciences as we fully transitioned to our.
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced financial results for the fourth quarter and fiscal year ended December 31, 2023 and provided a business update. “2023 was a transformative year for Precision BioSciences as we fully transitioned to our.